Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Egyesült Államok
- Anaheim · Anaheim Clinical TrialsIsmeretlen állapot
- Austin · Pinnacle Clinical ResearchIsmeretlen állapot
- Aventura · Translational Clinical Research LLCIsmeretlen állapot
- Fargo · Lillestol Research, LLCIsmeretlen állapot
- Fayette · Prime Health and Wellness Sky Clinical Research Network GroupIsmeretlen állapot
- Jacksonville · Clinical Neuroscience Solutions - JacksonvilleIsmeretlen állapot
- Lake Forest · Orange County Research CenterIsmeretlen állapot
- Lauderhill · South Florida Clinical Research Institute - LauderhillIsmeretlen állapot
- Miami · Clinical Pharmacology of Miami, LLCIsmeretlen állapot
- Miami · New Horizon Research CenterIsmeretlen állapot
- Orlando · Clinical Neuroscience SolutionsIsmeretlen állapot
- Oxnard · Fomat Medical ResearchIsmeretlen állapot
- Union City · Rophe Adult and Pediatric Medicine/Sky Clinical Research Network GroupIsmeretlen állapot
The registry text, word for word
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Inclusion: Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) of 30.0 kg/m\^2 to 40.0 kg/m\^2 for Part A and BMI of 27.0 kg/m\^2 to 40.0 kg/m\^2 for Part B; Females enrolled must be of non-childbearing potential.
Exclusion: History and/or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dL (7 mmol/L) at screening; Triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL) at screening.